Skip to main content
Princy Kumar, MD, Infectious Disease, Washington, DC, MedStar Georgetown University Hospital

PrincyNirmalKumarMD

Infectious Disease Washington, DC

Associate Professor of Medicine, Georgetown University

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kumar's full profile

Already have an account?

Education & Training

  • MedStar Health/Georgetown University Hospital
    MedStar Health/Georgetown University HospitalFellowship, Infectious Disease, 1988 - 1990
  • Hackensack University Medical Center/Englewood Hospital and Medical Center
    Hackensack University Medical Center/Englewood Hospital and Medical CenterResidency, Internal Medicine, 1985 - 1988
  • Kasturba Medical College Manipal
    Kasturba Medical College ManipalClass of 1980

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 1988 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2013-2014
  • Top Doctors:Washington DC Area Castle Connolly, 2012
  • Top Doctors:Washington-Baltimore Castle Connolly, 2012
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1  
    Princy Kumar, MD, The New England Journal of Medicine

Press Mentions

  • Kumar Honored for Response, Mentorship During the Pandemic
    Kumar Honored for Response, Mentorship During the PandemicApril 29th, 2022
  • MedStar Health Treats 1000th COVID-19 Patient with Monoclonal Antibody Therapy
    MedStar Health Treats 1000th COVID-19 Patient with Monoclonal Antibody TherapyMarch 17th, 2021
  • The Cost-Effectiveness and Budget Impact of Ibalizumab-Uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States
    The Cost-Effectiveness and Budget Impact of Ibalizumab-Uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United StatesFebruary 3rd, 2021
  • Join now to see all

Hospital Affiliations